Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
CONVATEC GRP UNSP.ADR /4
CNVVYConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies in Europe, North America, and internationally. The company offers advanced wound care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, bladder cancer, inflammatory bowel disease, and trauma. In addition, the company offers continence care products and services for people with urinary continence issues related to spinal cord injuries, neurological disease, prostate enlargement or other causes. Further, it provides infusion care solutions comprising disposable infusion sets for diabetes insulin pumps, or for used in continuous infusion treatments for conditions such as Parkinson's disease. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. ConvaTec Group PLC was founded in 1978 and is headquartered in London, the United Kingdom. Address: 20 Eastbourne Terrace, London, United Kingdom, W2 6LG
Analytics
Zielpreis von Wall Street
–KGV
34.86Dividendenrendite
1.90 %Schlüsselzahlen CNVVY
- Gewinnspanne
- Gesamtumsatz
- Bruttogewinn
- Nettogewinn
Dividenden-Analyse CNVVY
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y>5 - expected 5-9 dividend yield on cost over 10Y<5 - expected <5 dividend yield on cost over 10YMaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
2 JahreAusschüttungsquote 5-Jahres-Durchschnitt
–Verlauf der Dividende CNVVY
- Auszahlungsquote
- Dividends
- Dividendenrendite
Bewertung der Aktie CNVVY
- KUV
- KGV
- Kurs-Buchwert-Verhältnis
- Liquiditätsgrad
- Verschuldungsgrad
Finanzen CNVVY
Ergebnisse | 31.12.2020 | 31.12.2021 | 31.12.2022 | 31.12.2023 | 31.12.2024 | Dynamik | |
Gesamtumsatz | - | - | - | - | - | ||
Betriebseinnahmen | - | - | - | - | - | ||
Nettogewinn - (CF) | - | - | - | - | - | ||
Normalisiertes Basis-EPS | - | - | - | - | - | ||
Dividende pro Aktie | 0.24 EUR | 0.25 EUR | 0.24 EUR | 0.27 EUR | 0.28 EUR | ||
Auszahlungsquote | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | ||
Gesamtvermögen | - | - | - | - | - | ||
Gesamtverbindlichkeiten | - | - | - | - | - | ||
Verschuldungsgrad | - | - | - | - | - | ||
Gesamtumlaufvermögen | - | - | - | - | - | ||
Gesamtverbindlichkeiten | - | - | - | - | - | ||
Liquiditätsgrad | - | - | - | - | - | ||
Schnellliquiditätsgrad | - | - | - | - | - | ||
ROA | - | - | - | - | - | ||
FFO-Zinsdeckung | - | - | - | - | - | ||
KGV - P/E (LTM) | - | - | - | - | - | ||
Dividendenrendite (LTM) | 2.39 % | 2.83 % | 2.48 % | 2.46 % | 2.68 % | ||
Rückkaufrendite (LTM) | - | - | - | - | - |